CALIFORNIA | LOCAL
March 29, 2013 | By Scott Glover and Lisa Girion, Los Angeles Times
Despite efforts by law enforcement and public health officials to curb prescription drug abuse, drug-related deaths in the United States have continued to rise, the latest data show. Figures from the U.S. Centers for Disease Control and Prevention reveal that drug fatalities increased 3% in 2010, the most recent year for which complete data are available. Preliminary data for 2011 indicate the trend has continued. The figures reflect all drug deaths, but the increase was propelled largely by prescription painkillers such as OxyContin and Vicodin, according to just-released analyses by CDC researchers.
CALIFORNIA | LOCAL
March 26, 2013 | By Lisa Girion and Scott Glover, Los Angeles Times
A top DEA official is calling on federal regulators to impose tougher rules on the way pharmaceutical companies market narcotic painkillers to physicians, noting that such drugs are involved in more than twice as many deaths as heroin and cocaine combined. Joseph T. Rannazzisi, who heads the Drug Enforcement Administration's Office of Diversion Control, urged the Food and Drug Administration in a letter to adopt stricter limits on OxyContin, Vicodin and similar medications to "safeguard the American public.
BUSINESS
October 26, 2012 | Ronald D. White
Occidental Petroleum Corp. and ConocoPhillips posted lower earnings but still beat analyst expectations, leading off what is expected to be a weaker third-quarter earnings performance for the U.S. oil and gas industry compared with a year earlier. Occidental, the nation's fourth-biggest oil and gas company, reported net income of $1.4 billion, or $1.70 a share, compared with a profit of $1.8 billion, or $2.18 a share, in the third quarter of 2011. Analysts had been expecting the Westwood company to report $1.63 a share, according to Thomson Reuters.
BUSINESS
October 25, 2012 | By Ronald D. White
Occidental Petroleum Corp. of Westwood led off what is expected to be a lower third-quarter earnings performance for the oil and gas industry compared to a year ago. But the company still made a $1.4-billion profit while setting another production record. Occidental is the nation's fourth biggest oil and gas company. It's $1.4-billion and $1.70-a-share performance compared with a profit of $1.8 billion and $2.18 a share in the third quarter of 2011. The main difference in performance involved lower commodity prices.
BUSINESS
January 25, 2012 | By Ronald D. White, Times Staff Writer
Occidental Petroleum Corp. kicked off the oil industry's fourth-quarter earnings results Wednesday. It announced a net profit increase of 35% to $1.63 billion compared to the same quarter a year ago as the company rode the crest of a high oil-price wave and record U.S. crude production levels. Westwood-based Occidental is the nation's fourth largest oil exploration and production company. It has a reputation among analysts as being one of the industry's best managed firms. In 2011, Occidental and the rest of the oil industry enjoyed the highest average oil prices ever, but analysts said the company is built to maximize earnings even when oil prices are low. "In our view," said Phil Weiss, an oil industry analyst with Argus Research, "Occidental's low cost structure and use of enhanced oil-recovery techniques to increase production and build reserves will enable it to maintain strong cash flow and profitability in almost any price environment.
NEWS
March 2, 2011 | By Thomas H. Maugh II, Los Angeles Times
Consuming opioid pain relievers such as codeine, oxycodone or hydrocodone just before pregnancy or early in pregnancy increases the risk of certain birth defects, especially congenital heart defects, the Centers for Disease Control and Prevention warned Wednesday. The warning extends to such prescription painkillers as Vicodin, OxyContin and Tylenol-3, as well as a variety of generic versions of the drugs. Although there is an increased risk of some major types of birth defects from exposure to the drugs, "the absolute risk for any individual woman is relatively modest," said epidemiologist Cheryl S. Broussard of the CDC's National Center on Birth Defects and Developmental Disabilities, who led a study of the drugs that will be published in the American Journal of Obstetrics and Gynecology . The findings come from the ongoing CDC-sponsored National Birth Defects Prevention Study , the largest study of birth defects ever performed in the United States, covering pregnant women in 10 states, including California.